Onesource Specialty Pharma Limited — Board Meeting, 04-08-2025: Outcome of Board Meeting

OneSource Specialty Pharma has announced a board meeting on August 4, 2025, where it approved the consolidated financial results for the quarter ended June 30, 2025. The company reported revenue from operations of Rs. 327.27 crore. It posted a slight consolidated loss after tax of Rs. 0.19 crore, impacted by Rs. 2.87 crore in legal charges related to ongoing legacy litigation. OneSource also fully repaid its listed non-convertible debentures, with associated security released. A major update includes a pending arbitration regarding a USD 136.32 million (approx. Rs. 1,167.60 crore) claim from Prestige Biopharma over the Sputnik vaccine contract, which the company disputes.